Abstract
AbstractHydrogen sulfide (H2S), a gaseous signaling molecule, is excessively produced in disease lesions like lung tumors and colorectal tumors. H2S is used as a trigger for stimuli‐responsive drug delivery in cancer therapies, which enables controlled release of chemotherapeutics and improves their biocompatibility and efficacy. Herein, a H2S‐responsive small‐molecule nanocarrier is developed based on the self‐assembly of a trigonal molecule, tris(azido benzyl)‐tri(2‐aminoethyl) amine (ATAEA). ATAEA with three H2S‐responsive azido benzyl groups can self‐assemble into nanocarriers (ATNPs) and encapsulate hydrophobic doxorubicin (DOX) to form drug‐loaded nanoparticles (DOX/ATNPs). H2S induces the reduction of azido benzyl group and 1,6‐elimination, which results in the dissociation of the ATAEA molecules and the nanoparticles. In HCT116 colon cancer cells, efficient H2S‐responsive DOX release from DOX/ATNPs is observed. In vivo administration of DOX/ATNPs in colon tumor‐bearing mice leads to higher drug accumulation in tumors and evident tumor growth inhibition, in comparison with non‐responsive nanoparticles. This work provides a new strategy to develop H2S‐responsive drug delivery systems for precise drug delivery to H2S‐enriched disease lesions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
